A bogus vet who pleaded guilty to a number animal cruelty and fraud offences is being sought by Humberside Police after he failed to appear at court for sentencing.
Jayson Paul Wells (pictured right), 30, of Driffield in the East Riding of Yorkshire, is wanted by detectives in Grimsby after he failed to appear at Grimsby Crown Court.
The RCVS assisted Humberside Police with its original investigation and is publicising its appeal to help locate Mr Wells. Police believe that he may be trading as a herdsman in Nottingham or Cornwall and are keen to establish whether he is currently in either location.
Mr Wells was arrested on 2 October 2013 and charged with the following offences:
Mr Wells pleaded guilty to all offences.
Anyone who is aware of his whereabouts is asked to call Humberside Police on 101 or call Crimestoppers anonymously on 0800 555 111.
Bayer Animal Health has launched Baytril® Max 100mg/ml Solution for Injection for Cattle and Pigs, which replaces the company's previously animal-specific Baytril Max products.
Bayer says the active ingredient, enrofloxacin, treats bacterial infection by inhibiting the action of bacterial DNA gyrase resulting in bacterial cell death.
In cattle, Baytril Max treats respiratory infections and mastitis caused by enrofloxacin-sensitive Histophilus somni, Mannheimia haemolytica, Pasteurella multocida and Mycoplasma spp., and enrofloxacin-sensitive E. coli respectively.
In pigs, Baytril Max targets bacterial bronchopneumonia caused by enrofloxacin-sensitive Actinobacillus pleuropneumoniae, Pasteurella multocida and complicated by Haemophilus parasuis as a secondary pathogen in pigs.
Bayer advises that vets treating cattle for respiratory infections should inject subcutaneously. Mastitis cases should be treated intravenously and pigs should be injected intramuscularly in the neck muscles, behind the ear.
The development of the Baytril Max product family provides vets with greater treatment flexibility from one solution.
For further information please visit www.noahcompendium.co.uk
Mr Chalkley faced three charges against him. The first was that he failed to identify some or all of the animals tested with Intradermal Comparative Tuberculin (ICT) tests at the farm.
The second charge was that Mr Chalkley had certified that he had carried out ICT tests on 279 animals at the farm and recorded the results on the accompanying paperwork but had, in fact, not adequately identified some or all of the 279 animals and had fabricated the skin thickness measurements recorded for some of them.
In addition, the charge alleged that Mr Chalkley’s conduct was dishonest, misleading and risked undermining government testing procedures designed to promote public health.
The third charge was that between June 2011 and September 2018, Mr Chalkley received payment of approximately £20,000 for ICT tests when, as a result of his conduct in relation to ICT tests at the farm, he was not entitled to such payment.
At the outset of the hearing Mr Chalkley admitted the first charge, that he had not adequately identified some of the animals.
On the third day of the hearing, during his evidence to the Committee, he admitted that his certification of the ICT testing was therefore misleading.
He denied the rest of the charges including that his conduct had been dishonest and that it had risked undermining government testing procedures designed to promote public health.
In considering the charges against Mr Chalkley, the Committee heard that discrepancies regarding the tests that were carried out on the farm in March 2018 were originally raised by the Animal and Plant Health Agency (APHA), on whose behalf Mr Chalkley carried out ICT testing in his capacity as an Official Veterinarian.
When Mr Chalkley gave evidence during the hearing, he explained that he had taken over TB testing for the farm in 2008 and that working conditions on the farm had been difficult throughout the whole period 2008 to 2018. He stated that due to the harsh weather conditions of early 2018, TB testing was difficult, and that the farmer needed to complete the test by March 2018 to avoid a financial penalty.
Mr Chalkley explained that one of the reasons for there being limited time available for him to carry out the test within the time required by the farmer was that he was due to provide veterinary cover at the Cheltenham races the following week and he was unable to find anyone else to cover the tests. Mr Chalkley also explained that during the tests on 5 and 8 March there had been limited farmhands available to assist in processing the cattle through the tests.
In the course of being asked questions by counsel for the RCVS, Mr Chalkley accepted that he had failed to identify some 45% of the animals he had injected on 5 March 2018 and had, in respect of each of the skin thickness measurements for those animals, randomly chosen a figure that he believed would be appropriate based on the breed, age and sex of the animal.
The APHA guidelines state that specific measurements should be made and recorded for each individual animal using callipers. Mr Chalkley said that he could not remember seeing the “pop-up” declaration which appeared when submitting the results to the APHA online and had never read it. He stated that he was not aware that he was making a declaration. However, he accepted that as an Official Veterinarian he was confirming that he had carried out the test properly. While he agreed that he knew that the test contained inaccuracies, he did not accept that he was being dishonest when he submitted the results.
Having considered all the evidence put forward by the RCVS and Mr Chalkley in his own defence, the Committee found that Mr Chalkley had acted dishonestly in deliberately choosing not to take the measurements on 5 March and had instead submitted fabricated alternatives, and so risked undermining public health by failing to carry out his duties as an OV.
The Committee also concluded that Mr Chalkley had been acting dishonestly, as he knew that he was submitting the test results as if they were the authentic outcome of a properly conducted test when in reality, they were no such thing.
The Committee did not accept Mr Chalkley’s evidence that he was unaware of the declaration which accompanied the submission of the test outcome. The Committee therefore found both the first and second charges proved.
In respect of the third charge the Committee found that this was not proven noting that the RCVS had not disproved Mr Chalkley’s explanation regarding his reasons for returning the £20,000 in fees he had received for carrying out TB testing at the farm from the APHA since 2011.
The Committee then considered whether the first two charges, both of which had been found proven, amounted to serious professional misconduct.
Ian Arundale, chairing the Committee and speaking on its behalf, said: “The Committee was prepared to accept that the respondent considered the risk arising from his actions as negligible. Nonetheless, in the Committee’s assessment a real risk existed due to the respondent’s actions and it was precisely the risk which the authorised testing procedure was designed to negate. The simple fact is the respondent could not be sure that each animal he assessed on 8 March 2018 had also been seen by him on 5 March 2018.
“However, the wider point with which the Committee was concerned related to the importance of any member of the profession or public being able to rely absolutely on the integrity of veterinary certification. Those parts of the Code and supporting guidance [concerning certification]… were unequivocal. It was very difficult to conceive of circumstances in which it could ever be justifiable to certify the outcome of a test which had not, in fact, been conducted in a way which was demonstrably valid and reliable. Such conduct was bound to be regarded as disgraceful by members of the profession and the general public.
“Honesty is the bedrock of appropriate certification and the Code and Guidance for the Disciplinary Committee is also unequivocal. Dishonesty in professional practice is always an extremely serious matter and the respondent’s responsibilities in the discharge of his functions as an Official Veterinarian were clear. On this occasion those responsibilities had been compromised.
“For these reasons, the Committee has come to the conclusion that the respondent’s conduct in relation to the facts found proved was disgraceful conduct in a professional respect.”
The Committee then went on to consider the sanction for Mr Chalkley.
The Committee heard oral evidence in mitigation, including from a former colleague who had worked with him in practice since 2006, as well as receiving a large number of written testimonials from various sources that attested to his honesty, integrity, willingness to help others, and charitable work in support of animal welfare.
Mr Chalkley’s counsel, in mitigation, highlighted his long and previously unblemished career, and characterised the conduct as an inexcusable but explicable error of judgement that was entirely isolated and out-of-character. Mr Chalkley’s counsel added that he had not done anything that he thought was seriously wrong, and there was no evidence that any harm had been done and that any risk to public health was not serious.
The Committee accepted that the conduct was isolated and out-of-character and that, furthermore, Mr Chalkley had made early and frank admissions to the APHA and that he had displayed a degree of insight, although the Committee was less confident that he truly understood the seriousness of the potential consequences of his dishonest conduct.
The Committee took into account the aggravating factors, including Mr Chalkley’s breach of trust of his position as an OV, the undermining of the integrity of veterinary certification, dishonesty and the potential public health impacts of his conduct.
Ian Arundale added: “The Committee considered that, having regard to the mitigating features which it had identified, a suspension order would be sufficient to send to the profession and the public a clear signal about the importance to be attached to accurate certification. The Committee considered that in the particular circumstances of this case, a period of three months suspension would be sufficient to achieve this objective.”
The full findings for the case can be found at: www.rcvs.org.uk/disciplinary
Unite, the largest trade union in the country, has announced that up to 17,000 members of the UK veterinary profession could become members within the next five years, following the establishment of the British Veterinary Union (BVU)The union says it will be able to give veterinary surgeons, veterinary nurses, practice managers, support staff and students in all disciplines, the additional muscle to tackle employment problems in the workplace, such as pay, contracts, bullying and professional development.Unite's General Secretary, Len McCluskey said: 'As a progressive trade union, Unite warmly welcomes BVU into the Unite family. The fact that a highly-regarded profession is looking to Unite for support in employment matters is an indication of the validity and relevance of trade unions in 2011 Britain.' Dr Shams Mir, Chairman, Professional Advisory Committee, British Veterinary Union in Unite said: 'Our biggest challenge will be to change the mindset of our profession to address the deep-trenched problems of working conditions and terms of employment for vets and nurses, and safeguarding their professional status. But, most importantly, we have to overcome the sense of fear amongst veterinary professionals in raising legitimate employment issues.''Veterinary professionals face the same problems in their working lives as any other health professionals, but never before have vets had a trade union to support and represent them. BVU in Unite is a great opportunity for the profession to develop and expand, and is a goal that many have aspired to for years. We believe that up to 17,000 veterinary professionals could join BVU in Unite in the next five years.'Dr Mir said that research has revealed that vets suffer from much higher levels of anxiety and depressive symptoms and they are five times more likely to have suicidal thoughts and four times more likely to commit suicide compared to the general UK population.
He said: 'Sadly, according to the most recent Royal College of Veterinary Surgeons' survey of the profession, nearly half of the responding vets and nurses said that if they had their time again, they would choose a different profession.' 'This is a wake-up call for our profession and we must act to address all the underlying problems leading to this situation.'
Further information is available at: www.bvu.org.uk and www.unitetheunion.org/bvu
The awards are designed to recognise successful implementation of quality improvement (QI) in veterinary practice, which can reduce avoidable errors, ensure practice is based on the best available evidence and, ultimately, save lives.
Entrants will need to demonstrate the impact that QI methods have had in their practice, such as increased efficiency, improved clinical or financial effectiveness, the development of a culture of continuous improvement, support in the use of evidence-based approaches, or a general bettering of excellence in care.
The awards are open to any member of a practice, including veterinary surgeons and nurses, practice managers, receptionists, locums, students, and more. You can also nominate a colleague, or vice versa.
Individual winners will get free tickets to an upcoming RCVS Knowledge event and be given a plaque pronouncing them a 'Knowledge Champion', while one team will scoop Knowledge’s 'Champion Practice' award.
RCVS Knowledge Executive Director Chris Gush said: "These awards are a great opportunity to celebrate the good work that is going on in practice and to highlight examples of quality improvement.
"I would encourage all – from quality improvement experts to QI beginners – to get involved and enter the awards."
The closing date to submit an application is 1st November 2018, allowing plenty of time for those interested in introducing a quality improvement initiative in their practice to do so and apply for the awards at a later date.
To learn more about QI and how you can get started, visit RCVS Knowledge's QI pages.
Alternatively, you can enter the awards here: https://knowledge.rcvs.org.uk/grants/available-grants/
The company says that recent supply issues have been due to 'incredible' demand for Reconcile since it was launched in the UK in 2022, which greatly surpassed expectations.
Dr Lucy Chadwick, Head of Technical Services & Marketing at Forte Healthcare Ltd said: “We realise that the recent supply issues have been very inconvenient so we thank all of our customers for their patience and support during this challenging time.
"We are confident that our supply issues to date have been resolved and that we have enough stock going forward to meet market demand.“
www.reconcilefordogs.com
whatstherisk.co.uk has been created for all practice staff and contains advice from parasitologists Ian Wright and Eric Morgan.
Topics include advice on practical risk assessments, how risk-based prescribing can work with health plans as well as how to get owners involved to make risk assessment and personalised prescribing quicker and simpler.
Boehringer says that all the materials and advice have been developed in line with RCVS Practice Standards and the BVA's guidance on the responsible use of parasiticides.1,2
Sharron Woods, NexGard brands Franchise Manager said: “With knowledge about parasitic risk low among dog owners, alongside increasing scrutiny on the potential overuse of parasiticides, we’re delighted to be at the forefront of supporting vets, pet owners and the wider industry in driving best-practice risk assessment and responsible parasite control."
References
The Veterinary Record has published what the British Homeopathy Association is calling the first ever systematic review of randomised controlled trials (RCTs) in veterinary homeopathy.
The review was conducted by Dr Robert Mathie, research development adviser to the association, and Dr Jürgen Clausen from the Carstens Foundation, Germany.
They found 18 placebo-controlled RCTs of veterinary homeopathy, published in the peer-reviewed literature, that were eligible for detailed assessment. Of these, only two were judged to provide reliable evidence. The remainder were unclear or had a high risk of bias.
The two studies which were judged reliable were:
HEKTOEN, L., LARSEN, S., ØDEGAARD, S. A. & LOKEN, T. (2004) Comparison of homeopathy, placebo and antibiotic treatment of clinical mastitis in dairy cows - methodological issues and results from a randomized-clinical trial. Journal of Veterinary Medicine. A, Physiology, pathology, clinical medicine 51, 439-446. In this study, homeopathy was shown to be ineffective.
Dr Mathie said: "Up to now, debates about the efficacy or effectiveness of veterinary homeopathy have been polarised by the absence of any systematic review of the subject. Our work clarifies the nature of the current RCT evidence."
Mr Mark Elliott, immediate past president of the British Association of Homeopathic Veterinary Surgeons, said: "This important study affirms that reliable evidence does exist and that more research should be done, particularly in light of current concerns about antibiotic resistance in production animals."
It seems a remarkable admission, that the entire veterinary homeopathy edifice rests upon one study in piglets. However, if that study did prove the efficacy of homeopathy, it would of course be an order of magnitude more remarkable than today's admission.
So, no pressure then, Camerlink et al!
This, says Spillers, suggests that older horses, whether or not they have been diagnosed with insulin dysregulation, need an appropriate diet and management plan to help minimise the risks associated with insulin dysregulation such as laminitis.
The two studies1,2, which were conducted in collaboration with Michigan State University, aimed to find out more about the relationship between insulin dysregulation, dietary adaptation, and ageing to help guide more appropriate feeding regimens for senior horses.
Both studies investigated tissue insulin resistance and the insulin response in healthy adults compared to healthy senior horses adapted to diets with varying levels and sources of hydrolysable and structural carbohydrate (starch, sugar, and fibre).
Results from both studies showed insulin responses tend to increase with age in healthy horses, regardless of the diet they had been fed prior to evaluation. The insulin response, for example, was highest in the senior horses fed a starch rich meal even when they had been adapted to such a diet.
Clare Barfoot, RNutr, the research and development manager at Spillers said: "These studies confirm that even healthy older horses can have an increased insulin response compared to younger animals.
"This suggests that the energy sources used in the diet of senior horses and their effect on insulin dynamics need to be carefully considered.
"Practically, this means restricting the overall amount of starch and sugar in the diet especially for those horses that already have additional risk factors such as obesity, native breeding or PPID."
The anti-emetic, Cerenia (maropitant citrate), has gained licenses for use in puppies from as young as eight weeks of age and in cats from 16 weeks of age in the prevention and treatment of vomiting and reduction of nausea.
Cerenia is an NK-1 receptor antagonist which Pfizer says is effective against both peripheral and central emetic stimuli by acting on the final common pathway for emesis. It is, according to the company, the only NK-1 receptor antagonist licensed for dogs and cats.
Pfizer adds that in addition to the use for general emesis in puppies, Cerenia can also be used for chemotherapy-induced nausea in dogs. Studies in human oncology show that some patients receiving chemotherapy consider nausea to be more distressing than vomiting1. and the use of NK-1 receptor antagonists has shown clear benefits in the prevention of nausea and vomiting in chemotherapy-treated humans2. Cerenia tablets are also for the treatment for motion sickness in dogs aged 16 weeks or older, delivering claimed efficacy up to 93% without sedating the dog.
Kate Grocott, Product Manager for Cerenia, said: "Already successfully used in the treatment and prevention of vomiting and chemotherapy nausea in dogs, the new licence is a positive step forward for the prevention and early treatment of vomiting for puppies as young as eight weeks of age and cats from 16 weeks old. Being able to deploy Cerenia in these cases, will improve quality of life, and increases the likelihood of the animal voluntarily taking food and water thereby assisting in the recovery where there is underlying disease."
The new licence for treatment of cats with Cerenia is associated with the injectable form, while puppies may be treated with either an injection or tablets.
For further information, contact your Pfizer Animal Health account manager or call 0845 300 8034.
A shift towards a more outcomes-based model of CPD for veterinary surgeons and veterinary nurses has been under discussion for a number of years and one of its main proponents has been the current RCVS Senior Vice-President Professor Stephen May (pictured right), who chaired the CPD Policy Working Party.
Stephen said: "There has been increasing recognition over a range of different professions that CPD records based on ‘inputs’ alone, for example, measuring the number of hours attending a lecture, do not necessarily prove that any significant learning has taken place or that this learning will be used to improve professional practice.
"By contrast, research has demonstrated that CPD activities focused on outcomes encourage professionals to reflect on what they have learned, how they will apply their learning and how it will improve their practice, which has a positive impact on professionalism and patient health outcomes. Numerous other professions, including human medicine and dentistry, have moved to this model and the veterinary world has been somewhat ‘behind the curve’ as a result.
"However, as with any significant shift in policy, there has been a recognition that we needed to take the profession with us and not force through change. This is why, in March 2017, we launched a pilot scheme for the outcomes-based model with veterinary and veterinary nurse volunteers, including people who, during the initial consultation stage, had voiced some skepticism towards the concept.
"The overall feedback from volunteers was very positive and supportive towards the changes and I look forward, over the coming years, to talking to the professions at large about the benefits of the approach and how to best engage with the model."
In all, around 120 volunteers took part in the pilot, of whom 70% were veterinary surgeons and 30% veterinary nurses. When the pilot finished in October 2018, volunteers provided feedback as part of the evaluation process. Of the 57% of volunteers (n=70) who responded to the survey:
77% said they would be willing to use an outcomes-based CPD model in the future;
41% found it ‘easy’ or ‘very easy’ to implement outcomes-based CPD while only 11% thought it was either ‘difficult’ or ‘very difficult’;
61% thought that the outcomes-based model made CPD more meaningful for them and 25% said it encouraged them to undertake a wider range of CPD activities than previously;
Other feedback included the need for a better CPD recording system and more information and guidance ahead of any future changes.
Following the feedback, particularly around the need for a new approach to CPD recording, it was also recommended to Council that a new online CPD recording system should be introduced. This system will integrate the current disparate systems, such as the Student Experience Log (for vet students), Nursing Progress Log (for student VNs) and the Professional Development Phase (for recent vet graduates), making it a ‘one-stop shop’ professional development recording platform.
Richard Burley, RCVS Chief Technology Officer, said: "We will be building a new platform, consolidating all professional development-related capability for all members, into a single, integrated solution, seamlessly accessible via our ‘My Account’ online portal, and forthcoming mobile app. We have assembled a new, dedicated, software development team to drive this work and more details about this system will be published in coming months."
Linda Prescott-Clements, RCVS Director of Education, added:"Following the approval of the CPD proposals by RCVS Council, a phased roll-out of the new model and the accompanying IT system will take place. This includes recruiting a group of volunteers from the profession later this year to get some initial feedback around the guidance resources and online CPD platform, with members of the profession being voluntarily able to sign up to the new model and IT system from January 2020 onwards.
"Implementation of the new CPD requirement for all members is expected to start in January 2022 but, prior to that, we will be working hard to talk to the profession about why an outcomes-based model is a more effective and meaningful way of undertaking CPD and this will include workshops, webinars and roadshows. Look out for more news on our plans over the coming months."
For more information about the College’s current CPD policy requirement and policy, visit: www.rcvs.org.uk/cpd
Pets at Home has announced the acquisition of the joint venture practice business, Vets4Pets, adding 93 stand-alone veterinary practices to the 116 in-store practices it already operates under the Companion Care brand.
Providing veterinary and grooming services to consumers is seen as the way for the retailer to overcome competition from the Internet.
Nick Wood, CEO of Pets at Home said: "The expansion of our veterinary business is a key element of our growth strategy for Pets at Home, providing additional services to our customers within our stores or close to our customers' homes. The acquisition of Vets4Pets is an important step in the delivery of this strategy. Vets4Pets is highly complementary to Companion Care, sharing fundamental beliefs and values, and is an excellent strategic fit for Pets at Home. I am delighted that Peter Watson has agreed to stay with the business. His knowledge and experience will be invaluable as we continue to build our veterinary business with both stand-alone and in-store practices. He will work closely with Jane Balmain, the Managing Director of our Companion Care business as we integrate the two businesses."
Peter Watson, Founder and CEO of Vets4Pets said: "Pets at Home holds a unique place in the retail landscape, built on a strong identity and a real passion for people and pets. It is clear to me that Nick and his team have a similar vision for their veterinary business. I'm delighted to be working with Nick to continue to expand the veterinary business by offering attractive joint venture opportunities for vets in stand alone locations to complement the offering in Pets at Home stores."
Companion Care MD, Jane Balmain added: "Companion Care and Vets4Pets each enjoy a strong reputation among both vets and customers. Both businesses have a common business model, offering joint venture partnerships with vets. I am looking forward to working alongside Peter as we bring the businesses together, continue to expand our joint venture partnerships and accelerate our growth."
Vets4Pets' UK operational centre will remain in the East Midlands, with its support functions being split between Companion Care's operation in Oxfordshire and Vets4Pets' Guernsey office.
For veterinary nurses, Schedule 3 is arguably one of the most important aspects of the Veterinary Surgeons Act, partly defining what it means to be a nurse, and defining what tasks veterinary surgeons can reasonably delegate.
Thus far, however, Schedule 3 has only been loosely defined, allowing for veterinary nurses to (under the direction of their veterinary surgeon employer) 'give medical treatment or carry out acts of minor surgery, not involving entry into a body cavity'.
There is evidence from the RCVS/BVNA VN Futures project that uncertainty about what this definition actually means in practice has stopped veterinary surgeons from delegating tasks which could both improve practice efficiency and make the role of the veterinary nurse more interesting, varied and rewarding.
The consultation - and the broader review of Schedule 3 of which it forms a part - aims to create a 'clarified and bolstered VN role via a reformed Schedule 3'.
Liz Cox, Chair of both the Schedule 3 Working Party and VN Council, said: "The future of veterinary nursing is both challenging and exciting, with the convergence of such factors as Brexit, the development of new technologies, and the increasing specialisation of veterinary surgeons, and we would very much like to know how you think the role of veterinary nurse will evolve.
"In light of this we very much encourage all veterinary nurses and veterinary surgeons to complete this consultation. Evidence gathered during the initial stage of the VN Futures project suggested that there is some uncertainty around the interpretation of Schedule 3 in clinical practice. For example, many veterinary nurses do not undertake Schedule 3 work or are uncertain as to whether they do, while some veterinary surgeons are reluctant to delegate Schedule 3 tasks to veterinary nurses.
"With this survey we hope to get a better steer on how Schedule 3 is used and interpreted in practice on a day-to-day basis and gather views on where both veterinary surgeons and veterinary nurses feel the current legislation could be clarified. Furthermore, we also want to know if there are areas of practice that are currently prohibited to nurses under current Schedule 3 arrangements that the professions believe could be opened up to veterinary nurses as a means of bolstering the profession."
Liz Cox and David Catlow MRCVS, Chair of the Standards Committee, will also be presenting a webinar on Thursday 11 May from 1pm to 2pm titled ‘The Art of Delegation – Schedule 3 Consultation’. It will focus on Schedule 3 and the role of the veterinary nurse, and explore possible areas to consider when responding to the consultation. To subscribe to the webinar, please visit The Webinar Vet’s website: www.thewebinarvet.com/webinar/art-delegation-schedule-3-consultation/
All eligible veterinary nurses and veterinary surgeons have been emailed with a link to survey.
Further information about the VN Futures project can be found at www.vetfutures.org.uk/vnfutures
Avonvale’s nurse dental champions are RVNs who have a special interest in dentistry. They receive additional career development and training, both in-house and via webinars. They also attend practical workshops.
They also get training and support materials from specialists at Eastcott Referrals, in Swindon.
They're then tasked with educating colleagues and clients about dental care and disease prevention.
Nurse dental champion, Jasmin Legge (picture right), said: "We increase owners' knowledge of what dental treatments can be performed at Avonvale and highlight the welfare benefits of dentistry to them.
"We give our patients a free consultation and take a look to see if they have any dental issues.
"If we believe they do, they will be referred to a vet for this to be confirmed and for them to assess what work is needed.
"We are also able to carry out scale and polishes on animals and we follow this up with educational post-dental checks, giving advice to owners on how to maintain good dental hygiene.
"Dental disease is a common problem and can cause misery for a lot of pets, which is why we want to do all we can to help alleviate the problem and to educate owners on how they can play their part.
"Here at Avonvale, when you have a particular area of interest, you are given amazing opportunities to help develop it. Nurse dental champions are a prime example of this."
The company says more and more CT scanners are being used in general practice, but many teams have been telling them they're not sure if they're using their scanner optimally, or that only some of the team are confident in using it.
The online training aims help teams get the best diagnostic use of CT
The first of the sessions, on 15th June, will cover the indications and benefits of CT in small animal practice.
The second on 22nd June will look at how and when to perform CT reconstructions.
Manuel Pinilla, VetCT Supporting Radiologist and Director of Quality Assurance (pictured right), will be delivering the talks.
Manuel said: “We are seeing a rapid increase in the use of CT in first opinion practice.
"We know CT can provide vital diagnostic information in addition to the more traditional modalities of x-ray and ultrasound.
"However, it can be challenging to optimise the diagnostic capability.
"We’re keen to support veterinary teams to help them get the most out of their machine and do the best for their patients and the owners.”
To register for the training, visit: https://welcome.vet-ct.com/ctcpdwebinars
The relevant section of the Government advice states: "This [key worker status] includes those involved in food production, processing, distribution, sale and delivery, as well as those essential to the provision of other key goods (for example hygienic and veterinary medicines)."
The RCVS/BVA statement, which is intended to help veterinary surgeons decide whether or not they can claim ‘key worker’ status and ask for their children to continue to be taken into schools, reminds veterinary surgeons to consider the wider societal picture and ensure that they only claim ‘key worker’ status if absolutely necessary.
The statement also stresses that the RCVS Code of Professional Conduct responsibility of the veterinary surgeon to take steps to provide 24-hour emergency first aid and pain relief to animals according to their skills and the specific situation continues, and veterinary practices will need to continue to carry out this work. It is important that animal owners are able to focus on their own health, and not need to worry about their pets. Both the RCVS and BVA believe that veterinary surgeons who are providing this essential work can be considered key workers.
The statement in full is as follows:
Veterinary surgeons as key workers in relation to school closures
RCVS and BVA appreciate that veterinary surgeons will feel a great deal of uncertainty at the present time, and that many will be facing considerable difficulties due to the closure of schools for most pupils.
The official government advice can be found here: https://www.gov.uk/government/publications/coronavirus-covid-19-maintaining-educational-provision/guidance-for-schools-colleges-and-local-authorities-on-maintaining-educational-provision.
The guidance emphasises that if children can be at home then they should be, in order to help to prevent the virus from spreading.
The government has granted key worker status by sector rather than profession. Some veterinary work will definitely fall into the ‘key worker’ category. RCVS and BVA are therefore providing some additional advice below, following consultation with the UK Chief Veterinary Officer:
SummaryAt this time the provision of public health and the maintenance of food production need to take priority, and veterinary surgeons working in these areas should be considered key workers.
Veterinary surgeons working in emergency care can also be considered key workers. This will not apply to every veterinary surgeon in clinical practice, and practices may need to consider rationalising their services to achieve this.
The guidance has been welcomed by both the BSAVA and BEVA. David Mountford, Chief Executive of BEVA said: "As veterinary professionals we are duty-bound to provide essential care, relieve suffering and protect the health of the public. Recognition as key workers in such circumstances is welcomed but we would encourage vets to only add to the burden faced by schools where animal welfare is at risk and all other avenues have been explored."
Norbrook Laboratories has launched Closamectin, a parasiticide which the company says will revolutionise cattle farming and parasite control in meat producing animals.
Closamectin Pour-on is a solution which can quite literally be poured onto the back of animals. It simultaneously treats fluke, worms and external parasites. The new product is the culmination of a six year research project costing £3.5 million and involving 80 scientists at the company's headquarters in Newry Co Down.
Norbrook says it will bring immense benefits for farmers whose cattle are often ravaged by parasitic attack. Fluke in particular can have devastating effects both on beef and dairy herds, seriously weakening, and in some cases killing the animals by destroying their livers. At the very least it collectively costs farmers around £17 million per annum by reducing the weight of beef cattle and the milk yields of dairy cows.
Fluke used to be confined to the western parts of Britain, together with Scotland and Ireland, but global warming has seen other parts of the UK experiencing the same mild and wet conditions on which the parasite thrives. Consequently it is on the rise.
Currently fluke is treated by injection or oral drench - both time-consuming and difficult processes for the farmers which can also be stressful for the animals. In contrast pour-on solutions can be applied swiftly and easily with no detrimental impact on cattle.
Norbrook has been awarded licenses for Closamectin Pour-on in both the UK and Ireland. This is a very significant market: the countries have a combined cattle population of 17 million. There are also plans to roll out the product in other countries.
Developing a pour-on to deal with these parasites has baffled scientists for 20 years. Alistair Couper, Norbrook's Chief Vet said: "This is the Holy Grail of farm animal veterinary medicine. It was a highly complex challenge for our research team. They had to develop a product which would treat different conditions simultaneously and have a molecular structure which could be absorbed straight through the skin. This is a ground breaking achievement and a brilliant piece of science"
Lord Ballyedmond, Chairman of Norbrook Laboratories said: "This is a very important milestone for Norbrook and for livestock and farmers worldwide. We have invested heavily in research and development and the results are there for all to see. We are delighted to have beaten other multinationals. We have now developed the world's most effective remedy for parasite control in cattle that our entering the food chain. I am pleased to state that our business has grown this year indigenously at 12% despite the recession, beating our competitors. This tremendous breakthrough is a great testimony to the brilliance of our scientists in Newry and also to our policy of investing in research. "
Medichem International has produced an A4 sized laminated poster which illustrates the correct way to wash and disinfect hands thoroughly.
The poster has a sticky back enabling it to be placed near to hand washing facilities in the practice.
If you would like copies of the poster, they are available free of charge by emailing info@medichem.co.uk and stating your name, practice, address and postcode.
Elanco Animal Health has highlighted the results of a new study1 which concludes that Duvaxyn IE-T Plus stimulates a highter protective antibody response than four other equine influenza vaccines commercially available in Ireland.
The trial compared the antibody responses of unvaccinated Thoroughbred weanlings following primary vaccination with Duvaxyn IE-T Plus, Equilis Resequin, Equip FT, Equilis Prequenza Te and ProteqFlu Te.
In addition, following the first vaccination, 43% of the weanlings failed to seroconvert. However, amongst those vaccinated with Duvaxyn IE-T Plus a 100% response rate was observed. The failure rate amongst vaccines other than Duvaxyn IE-T Plus ranged between 7.7% and 78.6%. By the time of the third vaccination (31 weeks after the first) all horses had responded to vaccination.
The study, conducted by the Irish Equine Centre in Johnstone, the Department of Life Sciences at the University of Limerick and the Department of Statistics at Trinity College in Dublin, involved 66 unvaccinated Thoroughbred weanlings on four different stud farms. Following primary vaccination (V1, V2 and V3) with the five vaccines antibody responses were monitored for six months post V3 by single radial haemolysis. Elanco says that the correlation between SRH antibody levels and protection has been well-established and accepted2.
Elanco also highlights a recent study3 which it says demonstrated the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course. The company says that this is believed to be the first demonstration of cross protection by a current UK equine influenza vaccine against a Florida sub-lineage clade 2 reference strain.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health said: "Most studies carried out by vaccine companies take place under controlled conditions that are optimal for effective vaccination. This latest study shows how well Duvaxyn IET plus stimulates immunity under field conditions against both vaccinal and non-vaccinal strains. Importantly, all the weanlings vaccinated with Duvaxyn seroconverted after the first vaccination, conferring earliest and most reliable protection for these vulnerable animals."
For further information please contact your local Elanco Companion Animal Health key account manager or phone 01256 779881.
References:
Elanco Companion Animal Health has launched of Dexdomitor 0.1 mg/ml, adding to its range of alpha-2 agonists and antagonists.
Produced and manufactured in partnership with Orion Corporation, Elanco says Dexdomitor 0.1 mg/ml contains all the properties of dexmedetomidine in a formulation that allows accurate and convenient dosing for the smallest patients. It can be used as a sedative for non-invasive, mild to moderately painful procedures and examinations which require restraint, sedation and analgesia in dogs and cats. It can also be used for deep sedation and analgesia in dogs in concomitant use with butorphanol for medical and minor surgical procedures and as a pre-medication in dogs and cats before induction and maintenance of general anaesthesia.
Dexdomitor 0.1 mg/ml has been designed to provide accurate dosing in very small dogs (up to 5kg) for sedation and pre-medication, small to mid-size dogs (up to 20kg) for pre-medication, and small cats (up to 3kg) for sedation and pre-medication.
Ed Whittle MRCVS, technical consultant at Elanco Companion Animal Health said: "With nearly a quarter of dogs weighing less than 6kg and nearly three-quarters weighing less than 23.1kg1, Dexdomitor 0.1mg/ml is ideal for small animals that require low concentration doses of dexmedetomidine for convenient and accurate dosing".
Elanco has has also produced a sedation and pre-medication dosing guide to educate veterinary professionals on the recommended doses for its range of alpha-2 agonists and alpha-2 antagonists.
For further information contact your Elanco Companion Animal Health key account manager or email elancoCAH.uk@elanco.com.
The intranasal vaccine can be administered to calves from one week old. It reduces the clinical signs of respiratory disease and viral shedding from infection with Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3V).
MSD says that no other UK-licensed BRD vaccine can be administered earlier in life, and claims the vaccine delivers the fastest on-farm protection, with an onset of immunity after administration of 5 days for BRSV and 7 days for Pi3V. Duration of immunity is 12 weeks for both viruses.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: "Having this early life calf pneumonia vaccine available in single dose vials will give farmers more practical leeway to be able to vaccinate vulnerable young calves from as young as a week of age, rather than delaying administration until a batch of calves are available. We know that early-age protection of young calves through intranasal vaccination can help prevent pneumonia and positively impact a beef or dairy calf’s productive future".
The new single dose vials are supplied in packs of five, complementing the five dose vials already available.
For further information, contact your MSD account manager.
The active ingredient of Clevor is ropinirole, which is a dopamine agonist with high selectivity for dopamine D2-type receptors1.
This, Animalcare says, means that Clevor only activates the receptors in the brain necessary to trigger emesis.
Clevor is also the only emetic product in the UK which is licensed for repeat-dosing1.
Clevor is available in packs of three eye dropper vials.
Each vial contains enough active ingredient to dose up to three, 20kg dogs at once, including a second dose if necessary1.
Kai Crawshaw, Animalcare UK Brand Manager said: ‘It’s hard to keep pets away from toxic substances so we are pleased to be able to offer vets a new treatment option for pet poisoning, just in time for Easter.
"Clevor is revolutionary in the field of emetics, offering veterinary practices a highly selective product with a non-invasive method of administration.
"We are confident that Clevor will quickly become a tried and trusted product of choice for those emergency situations.’
https://www.animalcare.co.uk/learn-more-about-clevor
Reference
The findings will be published in a freely-available and independently-authored report.
Jane Balmain, Chief Operating Officer at Vets4Pets (pictured right), said: “The last 18 months have been indescribably tough for everyone, not least the veterinary practice teams. Soaring levels of pet ownership coupled with recruitment challenges have meant that an already-stretched profession has been almost brought to its knees.
"As a profession, you’ve always put pets first. But now it’s time to also concentrate on you - the vets, nurses and support teams that make up our beloved sector. We want to hear how you’re feeling and give you the power to help us make change.
“By launching this sector-wide survey, we’re kick-starting a vital conversation to protect the wellbeing of vet teams and the future of the profession. We believe that, by sharing experiences openly and honestly from all corners of the sector, we can come together to bring about the much-needed changes to ensure it remains an attractive, long-term career option.”
The survey, which runs until 16th November 2021, can be completed at www.projectlisten.co.uk. Respondents will remain anonymous and no data will be collected via the survey.
Membra is a transparent, water-resistant, non-toxic, biodegradable bandage replacement consisting of a hydrogel polymer which can be applied to open wounds.
It is initially applied as a liquid and quickly gels into a thin, flexible layer over the site.
The initial liquid phase of Membra allows it to cover open and irregular spaces as well as suture lines and it dries in minutes to form a barrier that covers and protects the incision site or wound.
Being transparent, Membra allows the wound to be seen by the veterinary team and pet owners.
Membra lasts for up to 14 days and naturally biodegrades over time.
Animus says that Membra lowers the risk of infection or dehiscence.
The company also says that hydrogel polymer has been shown to replace the need for adhesive bandaging on suture lines following major TPLO surgery.
A study concluded that the polymer did not appear to raise the prevalence of incisional complications after TPLO surgery and lasts for 14 days, rather than 24-48 hours with traditional bandaging1.
Nick Butcher MRCVS, owner of Animus Surgical in the UK, said: “Regular bandaging of open wounds can be costly, time-consuming and stressful for owners and their pets, requiring frequent visits to the practice.
"The bandaging of some open wounds can be impossible because of the location of the lesion or the affected species (e.g. exotic or aquatic animals) and more aggressive or nervous patients may require sedation.
"Used bandages also add to the volume of clinical waste generated by the practice which requires incineration
“We are therefore delighted to launch Membra to veterinary teams in the UK.
"It has been very successful in the U.S. and we already have a number of UK vets using the product as Membra can positively affect the outcome of open wound management across a range of species, without the need for regular bandage changes.”
To find out how to apply Membra, a range of YouTube videos are available showing a selection of case examples: https://youtube.com/@sutureseal5917.
www.animussurgical.com.
Virbac has launched Prinovox, a new prescription-only spot-on ectoparasiticide for dogs and cats.
The company says the new product contains the same combination of Moxidectin and Imidacloprid as the market leader, but is offered with a unique and innovative pet owner engagement programme to help practices build loyalty, increase compliance and to encourage repeat purchase.
In dogs Prinovox is licensed for the treatment and prevention of lungworm; for the treatment and prevention of fleas and also for lice, mites, heartworm and roundworms. In cats, the licence covers fleas, mites, roundworm and heart worm. It can also be used for fleas and heartworm in ferrets.
Prinovox is available in six presentations to suit all weight ranges and in packs of four pipettes. The packaging uses the Blippar platform which owners can use to 'blip' interactive icons on the product's packaging with their smartphone to get more information on Prinovox, including a video on how to use it, a reminder system and a game.
In addition, the Prinovox support package includes:
Virbac's Head of Marketing Companion Animal, Simon Boulton MRCVS said: "We see the launch of Prinovox as a gamechanger. The ectoparasiticide market is one of the largest and most competitive in our industry and we are the first company to offer a product with the same efficacy as the market leader for all indications.
"We've gone one step further by increasing the value of the product to practices by developing a comprehensive parasite protection support package which harnesses the latest technology and consumer preferences for receiving information. We believe the efficacy of Prinovox, combined with the innovative support package we're offering, will make it a highly attractive product for practices and owners and we've been delighted at the feedback we've received so far."